Evolving management of early stage pancreatic adenocarcinoma in older patients

Sean Nassoiy, Wade Christopher, Rebecca Marcus, Jennifer Keller, Jessica Weiss, Shu Ching Chang, Richard Essner, Leland Foshag, Trevan Fischer, Melanie Goldfarb

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Due to the aging population, the number of older patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) will continue to rise. Study design: Utilizing the NCDB from 2010 to 2016, patients with early stage, clinically node negative PDAC who were ≥70 years old and had a Whipple were identified. Multivariable logistic regressions were used to determine independent factors for R0 resection and NAT. Cox-proportional-hazards regression analyses examined for the impact of NAT on the risk of death. Results: Of 5086 patients, 51.7% received upfront surgery + adjuvant therapy (UFS + AT), followed by 29.9% UFS only, and the remainder NAT. NAT significantly improved OS compared to a combined cohort of those that had UFS ± AT. NAT retained its independent survival benefit when compared to only patients that had UFS + AT. Conclusion: For older patients diagnosed with early stage PDAC, NAT was associated with improved R0 resection rates and a significant survival benefit when compared to the current standard of care.

Original languageEnglish
Pages (from-to)212-219
Number of pages8
JournalThe American Journal of Surgery
Volume225
Issue number1
DOIs
StatePublished - Jan 2023

Keywords

  • Elderly
  • Geriatric
  • Neoadjuvant chemotherapy
  • Pancreatic ductal adenocarcinoma
  • Resectable pancreatic cancer

Fingerprint

Dive into the research topics of 'Evolving management of early stage pancreatic adenocarcinoma in older patients'. Together they form a unique fingerprint.

Cite this